Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by (1,049)

Items 901–1,000 of 1,049

1. Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
   Vera Hirsh, Normand Blais, Ronald L. Burkes, Sunil Verma, Kenneth Croitoru · 2014 · Current Oncology
2. Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years
   Tanja Čufer, Tanja Ovčariček, Mary E.R. O'Brien · 2012 · European Journal of Cancer
3. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
   Youjin Kim, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Jong‐Mu Sun · 2018 · Cancer Research and Treatment
4. The biological functions and clinical applications of exosomes in lung cancer
   Rui Chen, Xin Xu, Zijun Qian, Congcong Zhang, Yongjie Niu, Zhixian Wang, Jianli Sun, Xiao Zhang, Yongchun Yu · 2019 · Cellular and Molecular Life Sciences
5. Phosphorylation events during viral infections provide potential therapeutic targets
   Julie A. Keating, Rob Striker · 2011 · Reviews in Medical Virology
6. The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
   Heidi E. Greulich · 2010 · Genes & Cancer
7. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial
   Satoshi Oizumi, Kunihiko Kobayashi, Akira Inoue, Makoto Maemondo, Shunichi Sugawara, Hirohisa Yoshizawa, Hiroshi Isobe, Masao Harada, Ichiro Kinoshita, Shoji Okinaga et al. · 2012 · The Oncologist
8. A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
   David Michael Jackman, Leigh A. Cioffredi, Lorraine Jacobs, Farhana Sharmeen, Linda K. Morse, Joan Vern Lucca, Scott Randall Plotkin, Paul J. Marcoux, Michael S. Rabin, Thomas James Lynch et al. · 2015 · Oncotarget
9. Practical Recommendations for Pharmacogenomics-based Prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics
   Laurent Becquemont, Ana Alfirevic, Ursula Amstutz, Hiltrud B. Brauch, Évelyne Jacqz-Aigrain, Pierre Laurent‐Puig, Miguel Ángel Molina‐Vila, Mikko Niemi, Matthias Georg Schwab, Andrew Alexander Somogyi et al. · 2010 · Pharmacogenomics
10. Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review
    Denis L. Fontes Jardim, Eric S. Groves, Philip P. Breitfeld, Razelle Kurzrock · 2016 · Cancer Treatment Reviews
11. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer
    Ulrich Baumgartner, Fabienne Berger, Ali Hashemi Gheinani, Sabrina Sofia Burgener, Katia Monastyrskaya, Erik Vassella · 2018 · Molecular Cancer
12. Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer
    Chengdi Wang, Yuxuan Wu, Jun Shao, Dan Liu, Weimin Li · 2020 · BMC Cancer
13. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
    Jair Bar, Nir Peled, Shiruyeh Schokrpur, Mirjana Wollner, Ofer Rotem, Nicolas Girard, Frank Aboubakar Nana, Sofie Derijcke, Waleed Kian, Sandip Pravin Patel et al. · 2022 · Journal of Thoracic Oncology
14. The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers
    Benjamin Izar, Lecia Van Dam Sequist, Mihan Lee, Alona Muzikansky, Rebecca Suk Heist, John Iafrate, Dora C. Dias-Santagata, Douglas J. Mathisen, Michael D. Lanuti · 2013 · The Annals of Thoracic Surgery
15. Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis
    Courtney J. Ensslin, Alyx C. Rosen, Shenhong Wu, Mario E. Lacouture · 2013 · Journal of the American Academy of Dermatology
16. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR , KRAS and ALK gene abnormalities
    Elizabeth Mary Gaughan, Daniel Botelho Costa · 2011 · Therapeutic Advances in Medical Oncology
17. EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
    Erjing Ke, Yi-Long Lung Cancer Wu · 2016 · Trends in Pharmacological Sciences
18. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer
    Christy W.S. Tong, William Ka Kei Wu, Herbert Ho-Fung Loong, William Chi Shing Cho, Kenneth K.W. To · 2017 · Cancer Letters
19. Tyrosine Kinase Receptors in Oncology
    Jorge Esteban-Villarrubia, J.J. Soto Castillo, Javier Pozas, María San Román, Inmaculada Orejana, Javier Torres-Jiménez, Alfredo Carrato, Teresa Alonso‐Gordoa, Javier Molina‐Cerrillo · 2020 · International Journal of Molecular Sciences
20. Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
    Juliann Chmielecki, Jeffrey S. Ross, Kai Wang, Garrett Michael Frampton, Gary A. Palmer, Siraj Mahamed Ali, Norma Alonzo Palma, Deborah Morosini, Vincent A. Miller, Roman Yelensky et al. · 2014 · The Oncologist
21. Lung cancer: Progress in diagnosis, staging and therapy
    Stephen G Spiro, Nichole T. Tanner, Gerard A. Silvestri, Sam M. Janes, Eric Kian Saik Lim, Johan Vansteenkiste, Robert Pirker · 2009 · Respirology
22. Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research
    David J. Stewart, Simon N. Whitney, Razelle Kurzrock · 2010 · Journal of Clinical Oncology
23. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations
    Shen, Yi-Cheng, Tseng, Guan-Chin, Tu, Chih-Yeh, Chen, Wei-Chun, Liao, Wei-Chih, Chen, Wei-Cheng, Li, Chia-Hsiang, Chen, Hung-Jen, Hsia, Te-Chun · 2017 · Lung Cancer
24. Personalized medicine for lung cancer: new challenges for pathology
    Keith M. Kerr · 2011 · Histopathology
25. Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR
    George Santis, Roger Angell, Guillermina Nickless, Alison Quinn, Amanda Herbert, Paul Cane, James F. Spicer, Ronan A. M. Breen, Emma McLean, Khalid Tobal · 2011 · PLoS ONE
26. Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone
    Spasenija Savic, Beata Bode, Joachim Diebold, Ivo Tosoni, Audrey Barascud, Betty Baschiera, Bruno Grilli, Michelle Herzog, Ellen Christina Obermann, Lukas Bubendorf · 2013 · Journal of Thoracic Oncology
27. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
    Seung Tae Kim, Ji Eun Uhm, Jeeyun Lee, Jong‐Mu Sun, Insuk Sohn, Seon Woo Kim, Sin‐Ho Jung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park et al. · 2011 · Lung Cancer
28. Quantifying EGFR Alterations in the Lung Cancer Genome with Nanofluidic Digital PCR Arrays
    Jun Wang, Ramesh Ramakrishnan, Zhe Tang, Weiwen Fan, Amy Kluge, Afshin Dowlati, Robert C. Jones, Patrick C Ma · 2010 · Clinical Chemistry
29. Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies
    Hao Tang, Sophia Mei Wang, G. Xiao, Joan H. Schiller, Vassiliki A. Papadimitrakopoulou, John Dorrance Minna, Ignacio Ivan Wistuba, Yang Xie · 2017 · Annals of Oncology
30. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary
    Nasser H. Hanna, David H. Johnson, Sarah Temin, Gregory A. Masters · 2017 · Journal of Oncology Practice
31. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion
    Matthias Preusser, Frank Winkler, Manuel Valiente, Christian Manegold, Elizabeth Cohen‐Jonathan Moyal, Georg Widhalm, Jörg‐Christian Tonn, Christoph Carl Zielinski · 2018 · ESMO Open
32. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma
    Silvia Mara Baez Rodriguez, A. El Kamel, Gheorghe Vasile Ciubotaru, Gelu Onose, Ani-Simona Sevastre, Veronica Sfredel, Suzana Dănoiu, Anica Dricu, Ligia Gabriela Tătăranu · 2023 · International Journal of Molecular Sciences
33. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review
    Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, Floryane Kim, Timothée Olivier, Xiuning Le, Alfredo Addeo · 2024 · Journal of Thoracic Oncology
34. Oncogenic KRAS‐induced interleukin‐8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non‐small cell lung cancer
    Noriaki Sunaga, Hisao Imai, Kimihiro Shimizu, David S. Shames, Seiichi Kakegawa, Luc Girard, Mitsuo Sato, Kyoichi Kaira, Tamotsu Ishizuka, Adi F. Gazdar et al. · 2011 · International Journal of Cancer
35. The evolving genomic classification of lung cancer
    David S. Shames, Ignacio Ivan Wistuba · 2013 · The Journal of Pathology
36. Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
    Helena Alexandra Yu, Gregory J. Riely · 2013 · Journal of the National Comprehensive Cancer Network
37. Histopathologic Characteristics of Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification
    Hyo Sup Shim, Da Hye Lee, Eun Ju Park, Se Hoon Kim · 2011 · Archives of Pathology & Laboratory Medicine
38. Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature
    Anthonie J. van der Wekken, Ali Saber, T. Jeroen N. Hiltermann, Klaas Kok, A. van den -->Berg, Harry J.M. Groen · 2016 · Critical Reviews in Oncology/Hematology
39. ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism
    Alona Zer, Mor Tal Moskovitz, David M. Hwang, Anat Hershko Klement, Ludmila Fridel, Grzegorz J. Korpanty, Elizabeth Dudnik, Nir Peled, Tzippy Shochat, Natasha B. Leighl et al. · 2016 · Clinical Lung Cancer
40. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
    Clara Mayo‐de‐las‐Casas, Núria Jordana‐Ariza, Mónica Garzón‐Ibáñez, Ariadna Balada‐Bel, Jordi Bertrán-Alamillo, Santiago Viteri, Noemı́ Reguart, M. A. Muñoz-Quintana, Pilar Lianes Barragán, Carlos Camps et al. · 2017 · Annals of Oncology
41. Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer
    Lina Li, Shuimei Luo, Heng Lin, Haitao Yang, Huijuan Chen, Ziyuan Liao, Wanzun Lin, Weili Zheng, Xianhe Xie · 2017 · Journal of Thoracic Disease
42. Nanopaclitaxel Therapy: An Evidence Based Review on the Battle for Next-Generation Formulation Challenges
    Harshita, Md. Abul Barkat, Sarwar Beg, Faheem Hyder Pottoo, Farhan Jalees Ahmad · 2019 · Nanomedicine
43. Gefitinib
    Justyna K. Rawluk, Cornelius Florian Waller · 2018 · Recent results in cancer research/Recent Results in Cancer Research
44. Pulmonary toxicities from targeted therapies: a review
    Nicholas A. Barber, Apar Kishor Ganti · 2011 · Targeted Oncology
45. Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer
    Kyoko Okamura, Taishi Harada, Shuo Wang, Kayo Ijichi, Kazuto Furuyama, Takaomi Koga, Tatsuro Okamoto, Koichi Takayama, Tokujiro Yano, Yoichi Nakanishi · 2012 · Lung Cancer
46. Technical and implementation issues in using next-generation sequencing of cancers in clinical practice
    Danny Ulahannan, M B Kovac, Paul James Mulholland, Jean‐Baptiste Cazier, Ian P.M. Tomlinson · 2013 · British Journal of Cancer
47. Unraveling the Genetics of Cancer: Genome Sequencing and Beyond
    Kit Man Wong, Thomas J. Hudson, John D. McPherson · 2011 · Annual Review of Genomics and Human Genetics
48. Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?
    Silvia Calabuig Fariñas, Eloisa Jantus Lewintre, Alejandro Herreros‐Pomares, Carlos Camps · 2016 · Translational Lung Cancer Research
49. Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients
    Zhilei Lv, Jinshuo Fan, Juanjuan Xu, Feng Wu, Qi Huang, Mengfei Guo, Tingting Liao, Shuqing Liu, Xiaoli Lan, Shanshan Liao et al. · 2017 · European Journal of Nuclear Medicine and Molecular Imaging
50. RETRACTED: lncRNA UCA1 Promotes Gefitinib Resistance as a ceRNA to Target FOSL2 by Sponging miR-143 in Non-small Cell Lung Cancer
    Xiliu Chen, Zhongliang Wang, Fan Tong, Xiaorong Dong, Gang Wu, Ruiguang Zhang · 2019 · Molecular Therapy — Nucleic Acids · Retracted
51. Tumor‐associated macrophages correlate with response to epidermal growth factor receptor‐tyrosine kinase inhibitors in advanced non‐small cell lung cancer
    Fu‐Tsai Chung, Kang‐Yun Lee, Chih‐Wei Wang, Chih‐Chen Heh, Yao‐Fei Chan, Huan‐Wu Chen, Chih-Hsi Scott Kuo, Po‐Hao Feng, Ting‐Yu Lin, Chun‐Hua Wang et al. · 2011 · International Journal of Cancer
52. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma
    Gerber, Naamit K., Yamada, Yoshiya, Rimner, Andreas, Shi, Weiji, Riely, Gregory J., Beal, Kathryn, Yu, Helena A., Chan, Timothy A., Zhang, Zhigang, Wu, Abraham J. · 2014 · International Journal of Radiation Oncology*Biology*Physics
53. A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer
    Peter M. Ellis, Normand Blais, D. Soulieres, Diana N. Ionescu, Meenakshi Kashyap, Geoffrey Liu, B. Melosky, Tony Reiman, Phillip Romeo, Frances A. Shepherd et al. · 2011 · Journal of Thoracic Oncology
54. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
    Takeshi Yoshida, Lanxi Song, Yun Bai, Fumi Kinose, Jiannong Li, Kim C. Ohaegbulam, Teresita Muñoz-Antonia, Xiaotao Qu, Steven A. Eschrich, Hidetaka Uramoto et al. · 2016 · PLoS ONE
55. Precision medicine needs randomized clinical trials
    Everardo Delforge Saad, Xavier Paolettí, Tomasz Burzykowski, Marc E Buyse · 2017 · Nature Reviews Clinical Oncology
56. The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613
    Jordi Remón, Jessica Menis, Baktiar Hasan, Aleksandra Peric, Eléonora De Maio, Silvia Novello, Martin Reck, Thierry Berghmans, Bartosz Wasąg, Benjamin Besse et al. · 2017 · Clinical Lung Cancer
57. A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
    E‐E Ke, Qing Hua Zhou, Qiu-Yi Zhang, Jian Su, Zhihong Chen, Xu‐Chao Zhang, Chong‐Rui Xu, Jin‐Ji Yang, Hai‐Yan Tu, Hong‐Hong Yan et al. · 2017 · Journal of Thoracic Oncology
58. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
    Leduc, C., Merlio, J.P., Besse, B., Blons, H., Debieuvre, D., Bringuier, P.P., Monnet, I., Rouquette, I., Fraboulet-Moreau, S., Lemoine, A. et al. · 2017 · Annals of Oncology
59. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
    Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D’Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michèle Milella, Giampaolo Tortora et al. · 2020 · Cancers
60. Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
    Damien Reita, Lucile Pabst, Erwan Pencreach, Éric Guérin, Laurent Dano, Valérie Rimelen, Anne‐Claire Voegeli, Laurent D. Vallat, Céline Mascaux, Michèle Beau‐Faller · 2022 · Cancers
61. Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer
    Anna A. Gogleva, Dimitris Polychronopoulos, Matthias Pfeifer, Vladimir Poroshin, Michaël Ughetto, Matthew J. Martin, Hannah Thorpe, Aurélie Bornot, Paul D. Smith, Ben S. Sidders et al. · 2022 · Nature Communications
62. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight
    Ji Hye Min, Ho Yun Lee, Ho-Yeong Lim, Myung‐Ju Ahn, Keunchil Park, Man Pyo Chung, Kyung Soo Lee · 2011 · Cancer Chemotherapy and Pharmacology
63. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
    Christopher G. Azzoli, Giuseppe Giaccone, Sarah Temin · 2010 · Journal of Oncology Practice
64. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
    Mariacarmela Santarpía, Alessia Liguori, Niki Karachaliou, María González‐Cao, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Giuseppe Altavilla, Rafael Rosell · 2017 · Lung Cancer Targets and Therapy
65. Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor
    Koji Takano, Manabu Kinoshita, Masatoshi Takagaki, Mio Sakai, Souichirou Tateishi, Takamune Achiha, Ryuichi Hirayama, Kazumi Nishino, Junji Uchida, Toru Kumagai et al. · 2015 · Neuro-Oncology
66. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients
    Katharina König, Martin Peifer, Jana Fassunke, Michaela A. Ihle, Helen Künstlinger, Carina Heydt, Katrin Stamm, Frank Ueckeroth, Claudia Vollbrecht, Marc Christiaan Allardt Bos et al. · 2015 · Journal of Thoracic Oncology
67. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution
    Kaidi Li, Maojun Yang, Naixin Liang, Shanqing Li · 2017 · Oncology Reports
68. AJRCCM : 100-Y ear A nniversary . The Shifting Landscape for Lung Cancer: Past, Present, and Future
    Anil Vachani, Lecia Van Dam Sequist, Avrum E. Spira · 2017 · American Journal of Respiratory and Critical Care Medicine
69. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients
    Chong Hyun Suh, Hye Sun Park, Kyung Won Kim, Junhee Pyo, Hiroto Hatabu, Mizuki Nishino · 2018 · Lung Cancer
70. Lung Cancer in Republic of China
    Yung‐Hung Luo, Chao‐Hua Chiu, Chih-Hsi Scott Kuo, Teh‐Ying Chou, Yi‐Chen Yeh, Han‐Shui Hsu, Sang-Hue Yen, Yuan‐Hung Wu, James Chih‐Hsin Yang, Bin-Chi Liao et al. · 2021 · Journal of Thoracic Oncology
71. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
    Yoshihiko Sakata, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Hiroshi Kobe, Hirotaka Matsumoto, Takashi Yokoi et al. · 2021 · European Journal of Cancer
72. Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer
    Akito Hata, Hiroshige Yoshioka, Shiro Fujita, Kei Kunimasa, Reiko Kaji, Yukihiro Imai, Keisuke Tomii, Masahiro Iwasaku, Akihiro Nishiyama, Tadashi Ishida et al. · 2010 · Journal of Thoracic Oncology
73. Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing
    Sae‐Won Han, Hwang‐Phill Kim, Jong-Yeon Shin, Eun-Goo Jeong, Won‐Chul Lee, Kyung-Hun Lee, Jae‐Kyung Won, Tae‐Yong Kim, Do‐Youn Oh, Seock‐Ah Im et al. · 2013 · PLoS ONE
74. Multilevel mixed effects parametric survival models using adaptive Gauss–Hermite quadrature with application to recurrent events and individual participant data meta‐analysis
    Michael J. Crowther, Maxime P. Look, Richard D Riley · 2014 · Statistics in Medicine
75. Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)
    Jong‐Mu Sun, Ki Hyeong Lee, Sang-We Kim, Ki Hyeong Lee, Young Joo Min, Hwan‐Jung Yun, Hoon Kyo Kim, HONG SUK SONG, Yeul Hong Kim, Bong‐Seog Kim et al. · 2012 · Cancer
76. EGFR mutations in lung cancer: from tissue testing to liquid biopsy
    Francesca Fenizia, Antonella De Luca, Raffaella Pasquale, Alessandra Sacco, Laura Forgione, Matilde Lambiase, Alessia Iannaccone, Nicoletta Chicchinelli, Renato Franco, Antônio Rossi et al. · 2015 · Future Oncology
77. MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer
    Yan Feng, Praveena Shree Thiagarajan, Patrick C. Ma · 2012 · Journal of Thoracic Oncology
78. 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
    Matthias Benz, Ken Herrmann, Franziska Walter, Edward B. Garon, Karen L. Reckamp, Robert A. Figlin, Michael E. Phelps, Wolfgang Weber, Johannes G. Czernin, Martin Allen-Auerbach · 2011 · Journal of Nuclear Medicine
79. Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
    Alex Friedlaender, Giuseppe Luigi Banna, Umberto Malapelle, Pasquale Pisapia, Alfredo Addeo · 2019 · Frontiers in Oncology
80. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
    Cho, Byoung Chul, Felip, Enriqueta, Hayashi, Hidetoshi, Thomas, Michael, Lu, Shun, Besse, Benjamin, Sun, Tao, Martinez, Melissa, Sethi, Seema N, Shreeve, S Martin et al. · 2022 · Future Oncology
81. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
    Melanie Janning, Juliane Sueptitz, Corinna Albers, Pierre Delpy, Amanda Tufman, J.-L. Velthaus-Rusik, Martin Reck, Andreas Jung, Diego Erich Kauffmann-Guerrero, Irina Bonzheim et al. · 2022 · Annals of Oncology
82. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review
    Durga S. Borkar, Mario E. Lacouture, Surendra Basti · 2012 · Supportive Care in Cancer
83. The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma
    Benjamin Izar, Haiyu Zhou, Rebecca Suk Heist, Christopher G. Azzoli, Alona Muzikansky, Emily E.F. Scribner, Lindsay A. Bernardo, Dora C. Dias-Santagata, Anthony John Iafrate, Michael D. Lanuti · 2014 · Journal of Thoracic Oncology
84. Survival of lung adenocarcinoma patients with malignant pleural effusion
    Shang‐Gin Wu, Chong‐Jen Yu, Meng‐Feng Tsai, Wei‐Yu Liao, Chih-Hsin Yang, I‐Shiow Jan, Pan‐Chyr Yang, Jin‐Yuan Shih · 2012 · European Respiratory Journal
85. Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
    Katharine A. R. Price, Christopher G. Azzoli, Lee M. Krug, Maria Catherine Pietanza, Naiyer A. Rizvi, William J. Pao, Mark G. Kris, Gregory J. Riely, Robert T. Heelan, Maria E. Arcila et al. · 2010 · Journal of Thoracic Oncology
86. Repeatability of 18F-FDG PET/CT in Advanced Non–Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials
    Wolfgang Weber, Constantine A. Gatsonis, P. David Mozley, Lucy Hanna, Anthony Frank Shields, Denise R. Aberle, Ramaswamy Govindan, Drew A. Torigian, Joel S. Karp, Jian Q. (Michael) Yu et al. · 2015 · Journal of Nuclear Medicine
87. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
    Francesco Passiglia, Sérgio Rizzo, Massimo Di Maïo, Antonio Galvano, Giuseppe Badalamenti, Angela Listì, Leonardo Gulotta, Marta Castiglia, Fabio Fulfaro, Viviana Bazan et al. · 2018 · Scientific Reports
88. CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses
    Dongdong Mei, Yan Luo, Yan Wang, Jingshan Gong · 2018 · Cancer Imaging
89. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Natalie Andrews Wright, Glenwood D. Goss · 2019 · Translational Lung Cancer Research
90. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
    Yang Zhang, Yuanyuan Zeng, Ting Liu, Wenwen Du, Jianjie Zhu, Zeyi Liu, Jian‐An Huang · 2019 · Respiratory Research
91. Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
    Tao Jiang, Pingyang Wang, Jie Zhang, Yanqiu Zhao, Jianying Zhou, Yun Fan, Yongqian Shu, Xiaoqing Liu, Helong Zhang, Jianxing He et al. · 2021 · Signal Transduction and Targeted Therapy
92. Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration
    Mingyao Wang, Zhe Zhang, Jiangfeng Liu, Meiyue Song, Tiantian Zhang, Yi‐Ling Chen, Huiyuan Hu, Peiran B Yang, Bolun Li, Xiaomin Song et al. · 2022 · Signal Transduction and Targeted Therapy
93. Strategies for Identifying Predictive Biomarkers and Subgroups with Enhanced Treatment Effect in Clinical Trials Using SIDES
    Ilya A. Lipkovich, Alex A. Dmitrienko · 2014 · Journal of Biopharmaceutical Statistics
94. The economic case for precision medicine
    Sean P. Gavan, Alexander Thompson, Katherine Payne · 2018 · Expert Review of Precision Medicine and Drug Development
95. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
    Matthias Scheffler, Anne Maria Schultheis, Cristina Teixidó, Sebastian Yves Friedrich Michels, Daniela Morales-Espinosa, Santiago Viteri, Wolfgang Hartmann, Sabine Merkelbach‐Bruse, Rieke Nila Fischer, Hans‐Ulrich Schildhaus et al. · 2015 · Oncotarget
96. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy
    Chong-xian Pan, Hongyong Zhang, Clifford G. Tepper, Tzu‐yin Lin, Ryan R. Davis, James Keck, P. Ghosh, Parkash S. Gill, Susan D. Airhart, Carol Bult et al. · 2015 · PLoS ONE
97. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes
    Hengyi Chen, Wenxiu Yao, Qian Chu, Rui Han, Yubo Wang, Jianguo Sun, Dong Wang, Yongsheng Wang, Mengshu Cao, Yong He · 2015 · Cancer Letters
98. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
    Xu, Jianlin, Jin, Bo, Chu, Tianqing, Dong, Xue, Yang, Haitang, Zhang, Yanwei, Wu, Dan, Lou, Yuqing, Zhang, Xueyan, Wang, Huiming et al. · 2016 · Lung Cancer
99. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
    Troiani, Teresa, Napolitano, Stefania, Della Corte, Carminia Maria, Martini, Giulia, Martinelli, Erika, Morgillo, Floriana, Ciardiello, Fortunato · 2016 · ESMO Open
100. A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing
     Lizotte, Patrick H., Hong, Ruey-Long, Luster, Troy A., Cavanaugh, Megan E., Taus, Luke J., Wang, Stephen, Dhaneshwar, Abha, Mayman, Naomi, Yang, Aaron, Kulkarni, Meghana et al. · 2018 · Cancer Immunology Research